Human mesenchymal stem cells (hMSC) have immunomodulative properties and, associated with calcium phosphate (CaP) ceramics, induce bone tissue repair. However, the mechanisms of osteoinduction by hMSC with CaP are not clearly established, in particular the role of osteoclasts and macrophages. Biphasic calcium phosphate (BCP) particles were implanted with or without hMSC in the paratibial muscles of nude mice. hMSC increased osteoblastic gene expression at 1 week, the presence of macrophages at 2 and 4 weeks, osteoclastogenesis at 4 and 8 weeks, and osteogenesis at 4 and 8 weeks. hMSC disappeared from the implantation site after 2 weeks, indicating that hMSC were inducers rather than effectors of bone formation. Induced blockage of osteoclastogenesis by anti-Rankl treatment significantly impaired bone formation, revealing the pivotal role of osteoclasts in bone formation. In summary, hMSC positively influence the body foreign reaction by attracting circulating haematopoietic stem cells and inducing their differentiation into macrophages M1 and osteoclasts, thus favouring bone formation.
Introduction
Autologous bone grafts are considered the gold standard in bone regeneration because of their osteogenicity, osteoinductivity, osteoconduction and osteointegration characteristics [1] . However, the bone harvesting procedure requires a second surgical site, at which complications have been reported, and the quantity of bone available for grafting is limited.
Synthetic bone substitutes, particularly calcium phosphate (CaP) ceramics, have been proven safe and biocompatible and are widely used to fill bone defects in clinical indications such as dental, maxillofacial and orthopaedic augmentation [2, 3] . Despite having a similar chemical composition to bone mineral [1] and possessing osteoconductive properties, CaP ceramics lack the osteogenicity needed to support bone healing in critical size defects [4] thus limiting their clinical use to small bone defects where osteoconduction is sufficient. The use of bone marrow derived mesenchymal stem cells (MSC) in unison with synthetic biomaterial scaffolds may overcome the challenges of autologous bone grafting for the regeneration of large defects. Human MSC (hMSC) are easily isolated, expanded in culture and have the ability to differentiate into multiple lineages such as osteoblasts, chondrocytes and adipocytes [5] . In vitro, hMSC cultured on CaP differentiated into osteoblasts even without osteogenic supplements [6] and in vivo bone formation is achieved by the use of MSC with ceramic scaffolds in ectopic sites [7] and critical sized defects [8] . In addition to their regenerative properties, MSC are also known to have unique immunoregulatory properties [8, 9] . It has been demonstrated that transplanted hMSC promote wound healing by recruitment of host MSC to the wound site [10] and Song and colleagues elegantly showed the homing of bone marrow MSC to ectopic sites for bone formation by using a sex-mismatched dog model [11] .
An inflammatory reaction is expected following implantation of a biomaterial such as CaP due to the host response to a foreign body. During the innate inflammatory reaction, monocytes which circulate in the blood become tissue macrophages [12] . There is evidence that MSC can regulate the macrophage M1/M2 balance to the M2, IL-10 producing anti-inflammatory phenotype [13] , by secreting some M2 inducers such as interleukine-4 (IL-4), IL-13 [13] , IL-6 [14] , and prostaglandin E2 [15] . Bone is essential for a functioning immune system since immune cells originate in the bone marrow; however the significance of immune cells to bone tissue formation is less understood. Nonetheless, disordered bone formation occurs in autoimmune diseases and recently it was shown that ablation of macrophages inhibits intramembranous bone healing [16] . The contribution of macrophages to tissue engineered bone formation is unclear however.
While osteoclast activity is generally associated with bone resorption, it has been demonstrated in vitro that osteoclasts secrete mediators which induce the migration and osteogenic differentiation of MSC [17] . In addition, the Wnt/BMP signalling pathway and sphingosine-1-phosphate cytokines, secreted by osteoclasts, seem to be implicated in osteoblast precursor recruitment [18] . Furthermore, osteoclast ablation was found to inhibit ectopic bone formation by b-TCP [19] . However, the influence of transplanted MSC on osteoclast activity during in vivo bone formation is unknown.
In this study, the hypothesis that transplanted hMSC, associated with BCP granules, can mobilize circulating monocytes thereby favouring bone formation is tested. Specifically, we investigated the interactions of transplanted hMSC, macrophages and osteoclasts in ectopic ossification in nude mice. To further elucidate the contribution of osteoclasts to bone formation, we used an anti-mouse RANKL antibody depleting osteoclast in mice [20] .
Materials and methods

Biomaterials
Micro-porous biphasic calcium phosphate (BCP) granules of 0.5e1 mm in size and composed of HA/b-TCP in a ratio of 20/80 in weight were used as received by the supplier (MBCPþ ® , Biomatlante, Vigneux de Bretagne, France). Briefly, BCP granules were prepared by mixing calcium deficient apatite with organic pore makers, followed by compaction and sintering at 1050 C. The overall porosity (% vol) was 75 ± 5%, with a pore size distribution of 70% (0e10 mm), 20% (10e100 mm) and 10% (100e300 mm). Aliquots of 40 mg of BCP granules were prepared in Eppendorf centrifuge tubes sterilized by autoclaving at 121 C for 20 min.
hMSC isolation and culture
The human bone marrow mesenchymal stem cells (hMSC) were kindly provided by Prof. Markus Rojewski, Institute for Clinical Transfusion Medicine, Ulm, Germany. After receiving informed consent from adult donors, a bone marrow aspiration was performed under local anaesthesia by haematologists. The cells were seeded at low density on treated culture polystyrene flasks (Corning) and cultured in a-modified Eagle's medium (aMEM, LONZA), supplemented with 10% foetal bovine serum (FBS, Lonza), 100 UI/ml penicillin, 100 mg/ml streptomycin. hMSC were isolated by plastic adherence, amplified in culture until passage 4 in a humidified atmosphere at 37 C and 5% CO 2 . hMSC were characterized by flow cytometry as being positive for CD73, CD90, CD105 and negative for CD45. Multipotency was demonstrated by culturing cells in adipogenic, chondrocytic and osteogenic conditions, as previously described [21] . For the preparation of cell-loaded implants, 1.4 Â 10 6 viable hMSC suspended in 70 mL PBS were added to 40 mg sterile BCP particles. The average time between cell seeding and surgery was approximately 1 h.
In vivo experimental design
All animal handling and surgical procedures were conducted according to European Community Guidelines (2010/63/EU) for the care and use of laboratory animals. An animal experimentation protocol was prepared, submitted and approved by the local Ethic Committee (CEEA.2012.27).
In order to evaluate the influence of transplanted hMSC on bone formation, Adult nude NMRI Nu/Nu female mice (4 weeks old, body weight 20 g) were purchased from a professional stock breeder (Janvier Labs, France). The nude mice were kept in Hepa filtered closets with water and food ad libitum and were quarantined for a minimum of 10 days prior to surgery. The mice were randomly and equally divided into 2 groups: BCP particles alone (40 mg) and BCP þ hMSC (40 mg and 1.4 Â 10 6 viable cells) that were bilaterally implanted in paratibial muscles. Five mice from each treatment group (n ¼ 5) were followed for 1, 2, 4 or 8 weeks after surgery. Animals were placed under general anaesthesia by inhalation of isoflurane (2.5% Flucka, 1 L/min) and an intramuscular injection of the analgesic Buprenorphine (Buprecare 60 mL/kg, Axience) was performed 30 min before surgery. A skin incision of 0.5 cm was made for exposing the muscle, and fibres were taken away to create a pocket where BCP granules were inserted. Skin incisions were closed with sutures (Filapeau 4/0, Peters). The mice were euthanized under general anaesthesia by cervical dislocation.
To determine the impact of osteoclastogenesis on bone formation initiated by hMSC, 8 weeks experiments were reproduced in nude mice which received injections of mAb anti-RANKL. RANKL is a key factor for osteoclast differentiation and activation. Anti-RANKL is known to drastically inhibit the formation of TRAP positive multinucleated cells in vitro and in vivo [20] . Adult nude NMRI Nu/Nu female mice (n ¼ 4) were implanted with BCP alone (40 mg on left leg) and BCP þ hMSC (40 mg and 1.4 Â 10 6 viable cells, on right leg) and treated with a subcutaneous injection (50 mg dose) of antibody anti-mouse RANKL, kindly provided by Prof. Hideo Yagita, Department of Immunology, Juntendo University School of Medicine, Tokyo, three days before implantation. This same injection regime was repeated twice a week and animals were sacrificed after 8 weeks under general anaesthesia by cervical dislocation. Implants were sectioned after euthanasia to perform histology and RNA extraction.
Histological analysis
The muscles were excised, fixed in 4% paraformaldehyde, decalcified in a PBS solution with 0.5% paraformaldehyde 4.13% EDTA in a microwave decalcifying automat (KOS Histostation) at 46 C. Samples were then embedded in paraffin and 3 mm thick sections were cut. Three sections through each implant were attained for histological analysis. The sections were stained with Masson's Trichrome and qualitative/quantitative histological evaluations of soft-tissue in-growth and bone formation were performed. Masson's trichrome technique combines hematoxylin for cell nuclei (blue/ black), fuchsine for cytoplasm, muscle and erythrocytes (red) and light green solution for collagen (green). The quantity of new bone was measured in separate sections with the software ImageJ. The bone formation was evaluated according to:
Tartrate resistant acide phosphatase (TRAP) is highly expressed by osteoclasts and therefore can be used to stain these cells in histological sections. The sections were stained using a commercial TRAP staining kit (Acid Phosphatase Leukocyte Staining Kit, Sigma) following the manufacturer's instructions. Briefly, the staining solution was prepared with Fast Red TR salt (3.9 mM), naphthol AS-TR phosphate disodium salt (2.3 mM), NeN dimethylformamide (68 mM), and L(þ)-tartaric acid (100 mM) all diluted in sodium acetate buffer (0.1 M, pH 5.2). Deparaffinised sections were incubated in the solution for 90 min at 37 C and then counterstained with Mayer's hematoxylin. TRAP-positive stained cells appeared red. Qualitative/quantitative histological evaluations of osteoclasts were then performed.
In situ hybridization
In situ hybridization using the human-specific repetitive Alu sequence, which comprises approximately 5% of the total human genome was performed for identification of human cells. Sections were deparaffinized and rehydrated in graded series of ethanol and washed with tris buffered saline (TBS) tween 0.05% pH 7.6 three times for 5 min each under gently agitation. Slides were treated with 3% H 2 O 2 for 15 min at room temperature (RT) to block endogenous peroxidase activity, followed by three washes with TBS tween 0.05%. Sections were then treated with 10 mg/mL proteinase K (P2308, Sigma Aldrich, France) for 10 min at 37 C. After a further three washes for 5 min each in TBS tween 0.05%, sections were treated with 0.25% acetic acid in 0.1 M triethanolamine (TEA) pH 8.0 for 20 min at RT under agitation. Pre-hybridization was performed for 3 h at 56 C in a hybridization buffer containing 4 Â SSC (S6639, Sigma Aldrich France), 50% deionized formamide, 1 Â Denhardt's solution, 5% dextran sulphate and 100 mg/mL salmon sperm DNA and molecular grade H 2 O. Hybridization buffer was replaced by fresh hybridization buffer containing 70 nM DIG-labeled human locked nucleic acid (LNA) Alu probe 5DigN/5 0 -TCTCGATCTCCTGACCTCATGA-3 0 /3DigN (Exiqon, Vedbaek, Denmark) and then target DNA and the probe were denatured for 5 min at 95 C. Hybridization was carried out for 40 h at 56 C in a wet chamber. Sections were washed twice in 2 Â SSC, then twice in 0.5 Â SSC at 56 C for 10 min each time, followed by three washes in TBS tween 0.05%. Finally, the hybridized probe was detected by immunohistochemistry using biotin-SP-conjugated IgG fraction monoclonal mouse antidigoxin (Jackson Immunoresearch, Baltimore, USA) diluted 1/200 in PBS for 45 min at 37 C. After three washes in TBS tween 0.05% at RT, streptaperoxidase was added (1/200 in TBS tween 0.05%) for 45 min at 37 C before diaminobenzidine (DAB) substrate addition (Dako). Sections were counterstained with Gill-2 hematoxylin (Thermo Shandon Ltd, Runcorn, UK) dehydrated and mounted using Pertex (HistoLab Products AB, Sweden).
Immunohistochemistry
Immunohistochemistry was performed on deparaffinised and rehydrated sections with specific primary antibodies: CD146 antibody (ab75769, rabbit antimouse, 1/200, Abcam), F4/80 antibody (MCA4976, rat anti-mouse, 1/200, Serotec), iNOS antibody (ab15323, rabbit anti-mouse, 1/100, Abcam), CD206 antibody (ab64693, rabbit anti-mouse, 1/1000, Abcam), CD68 (MCA1815T, mouse antihuman, 1/100, Abd Serotex). All sections were counterstained using Gill's hematoxylin and mounted using permanent mounting medium. Tissue staining was viewed using Nanozoomer 2.0 Hamamatsu slide scanner.
The CD146 antibody was used to detect pericytes in the histological sections. CD146, also known as Mel-CAM, MUC18, A32 antigen and S-Endo1, is a membrane glycoprotein observed in pericyte that surround the endothelial layers [22] . The F4/80 antibody was used to detect macrophages M0. The antigen, F4/80, is well expressed in macrophages M0 in most tissues of the developing and adult mouse. The iNOS antibody was utilised in this study for the detection of macrophages M1. Inducible nitric oxide synthase (iNOS) is a enzyme catalysing the production of nitric oxide (NO) from L-arginine [23] . The presence of macrophages M2 was detected by the CD206 antibody. CD206, widely known as the mannose receptor (MR) or more precisely MR C type 1 (MRC1) is a type 1 transmenbrane protein involved in innate immunity [24] . The CD68 antibody was used to detect macrophages M0. CD68 is a member of the lysosome-associated membrane protein (LAMP)-1 family [25] . It is a transmembrane glycoprotein highly expressed by monocytes and tissue macrophages [26] .
Quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR)
Implants were sectioned after euthanasia to perform histology and RNA extraction. Thus, each half of implants were transferred into a 1 mL tube with and vigorously shaken to lyse the cells. Phase separation was performed using chloroform. RNA was recovered from the aqueous phase using isopropanol, and this was Table 1 . The primer sequence used were specific to mouse genome to only evaluate the host cells behaviour. Relative gene expression for osteoblastic markers, as alkaline phosphatase (Alp), Bone sialo protein (Bsp) and osteocalcin (Oc), for osteoclastic markers, as acid phosphatase tartrate resistant (Trap) have been evaluated.
Statistics
Statistical comparisons of gene target expression and histomorphometry were performed using Two-way ANOVA and Bonferroni post tests in GraphPad Prism 6.0 software. p values <0.05 were considered statistically significant.
Results
Bone formation is increased by transplanted hMSC
Histological analyses showed bone tissue and bone marrow formation at 4 and 8 weeks in all implants consisting of hMSC and BCP granules (bone incidence 5 out of 5) (Fig. 1A) . Conversely, there was no bone tissue at 4 weeks and only small quantities of bone formation without the presence of bone marrow at 8 weeks in the BCP group without cells (Fig. 1A) . Quantification by histomorphometry revealed a significant increase in bone formation with BCP plus hMSC at 4 and 8 weeks, compared with BCP alone (5 and 10 fold increase respectively, p < 0.001, Fig. 1B ). Supporting these findings, there was a significant up-regulation in the expression of mouse bone markers, bone sialo protein and osteocalcin, in BCP plus hMSC at 1 week compared to BCP alone (Fig. 1C) . In contrast to histological bone detection that increased between 1 and 8 weeks, the gene expression of these bone markers decreased after 1 week. This apparent discrepancy may be explained by the loss of efficiency in RNA extraction from mineral tissue compared to soft tissue.
Transplanted hMSC disappear from implanted site
The presence of hMSC in the implants was evaluated by in situ hybridization on histological sections and by gene expression of the specific human Alu sequence. As illustrated in Fig. 2A , human cells were detected at 1 and 2 weeks within the BCP plus hMSC implants, while they were not detected at 4 weeks. These results were corroborated by the relative gene expression of Alu sequence (Fig. 2B ) which detected human cells within BCP plus hMSC implants at 1 and 2 weeks, but with a large decrease of activity between 1 and 2 weeks (2 fold decrease, p < 0.001, Fig. 2B ). As expected, no human cell transcription was measured in the control group without human cells. Confirming the in situ hybridization results, human cell transcription was not detected within the BCP plus hMSC implants at 4 and 8 weeks.
Osteoclast activity is enhanced by transplanted hMSC
Distribution of osteoclasts at the implantation site was investigated by the TRAP staining. Representative stained sections showed a large production of this resorbing enzyme around the BCP granules (Fig. 3A) . Histomorphometry quantification confirmed that hMSC significantly increased osteoclast activity in the implants (more than a 2 fold increase, p < 0.001, Fig. 3B ). There was an increase in the relative gene expression of the mouse osteoclast markers Cathk and Trap at 1 and 2 weeks in both the BCP group and BCP þ hMSC group; however there was no difference between the two groups.
Mobilization of macrophages M0 and M1 to the implant site is enhanced by transplanted hMSC
The distribution of first innate immunological cells, macrophages M0 and M1 within the implants was detected in histological Ribosomal protein L19 TCGTTGCCGGAAAAACAC AGGTCACCTTCTCAGGCATC sections as illustrated in Fig. 4 . Macrophages M0, labelled by the antibody anti-F4/80, were distributed in fibrous tissue between the BCP granules, whereas, macrophages M1, labelled by the antibody anti-iNOS, were primarily located surrounding the BCP biomaterial (Fig. 4A) . Histomorphological quantification showed an increase in the mobilization of macrophages M0 and M1 to the implant site in the BCP plus hMSC group compared to BCP alone (Fig. 4B) . Specifically, macrophages M0 were increased by the presence of hMSC at 2 and 4 weeks and decreased thereafter, while macrophages M1 were significantly higher at 4 weeks as a consequence of hMSC. Presence of macrophages M2 was investigated by immunohistochemistry directed against CD206 and relative gene expression of CD206, FCGR2, CD163 (data not shown). However, few positive cells were detected and no difference between the BCP alone group and the BCP plus hMSC group was found. The presence of pericytes was also investigated by immunohistochemistry directed against CD146 and relative gene expression of vascular endothelial growth factor and matrix metallopeptidase 2. The implants were highly vascularised but no difference could be quantified between the BCP and BCP þ hMSC groups (data not shown). Moreover, CD146 and in situ hybridization of Alu sequence were performed on serial sections of each implant demonstrating that human cells did not colocolize in the vessel walls.
3.5. Anti-RANKL treatment induces simultaneous blockage of osteoclastogenesis and reduced bone formation Fig. 5 depicts 8 week implants in nude mice with or without anti-RANKL treatment which inhibits osteoclastogenesis. Blockage of osteoclast activity was successful with a significant decrease in TRAP staining compared to non-treated controls (Fig. 5A and D) . Interestingly, inhibition of osteoclastogenesis with anti-RANKL treatment also resulted in a dramatic reduction in bone formation (from 15% to 5%), as highlighted in Fig. 5B and D. Supporting these results, osteoclastic and osteoblastic gene expression were quantified and showed a considerable decrease with mouse anti-RANKL antibody treatment (Fig. 5E ). The distribution of M0 macrophages was studied by immunohistochemistry directed against CD68 (Fig. 5C) . The results showed no difference in the presence of macrophages between the untreated and mAb anti-RANKL treated groups. 
Discussion
The objective of the present study was to understand the underlying mechanisms of bone formation induced by the grafting of hMSC. To achieve this, micro-porous BCP granules were implanted in the paratibial muscles of nude mice with or without hMSC and the chronological events leading to osteoinduction were identified. Implantation of hMSC considerably enhanced and sped up bone formation. Human cells were not found within the implants at 4 weeks, proving their role as mediators rather than effectors of bone formation. The foreign body reaction was studied revealing that hMSC induced an early mobilization of circulating monocytes to the implantation site as the presence of macrophages and osteoclasts was significantly up-regulated, suggesting their implication in the mechanism of bone formation. To more precisely determine the contribution of osteoclasts to osteogenesis, implantations were repeated in nude mice treated with mAb anti-RANKL to deplete osteoclast formation and activation. Ablation of osteoclastogenesis significantly impaired bone formation, proving the pivotal role of osteoclastmediated bone formation. The implantation of hMSC with BCP ceramics in this study resulted in a 15 fold increase in bone formation compared to BCP alone. This finding is in agreement with other studies in bone defects [8] and ectopic sites [7] which show the bone-forming benefits of implanted MSC. However, the exact mechanisms by which implanted MSC mediate bone induction is unclear. In the past it was thought that the therapeutic effects of implanted MSC lay in their ability to differentiate into cells of different lineages, into boneforming osteoblasts in the case of bone tissue engineering. However, in this study the implanted MSC disappeared completely from the implantation site between 2 and 4 weeks and the newly formed bone tissue was exclusively of host origin, suggesting that the implanted MSC facilitate but do not participate directly in the bone formation. Indeed, it has been previously demonstrated that calcium phosphate granules implanted ectopically induced the homing of MSC from the bone marrow to the site of CaP particles implantation to form ectopic bone tissue [11] . Previous studies substantiate the large scale death of implanted MSC [8, 27] which is due to ischaemia [25] and lack of glucose [26] in the implant microenvironment. It has recently been shown that the viability of implanted MSC can be maintained in glucose supplemented implants [26] . Nevertheless, the maintained viability of implanted MSC was not necessary to initiate bone formation in this study.
The foreign body reaction against BCP biomaterial and hMSC was investigated in this study and it was found that BCP granules initiated a recruitment of cells of the monocyte/macrophage lineage, which was significantly potentiated by the addition of hMSC.
Attraction of macrophages to b-TCP particles was previously demonstrated in vitro, whereby macrophages migrated towards the biomaterial by emitting cytoplasmic extensions [28] . Furthermore, interactions of poly morphonuclear neutrophils with hydroxyapatite particles increase levels of pro-inflammatory mediators interleukin-8 (IL-8) and the matrix metallopeptidase 9 [29] , a possible mechanism contributing to the mobilization of monocytes and macrophages M1 to BCP. The further significant increase in mobilization of cells of the monocyte lineage by the addition of hMSC in our study, may be explained by the secretion of monocyte chemo-attractant protein-1 by implanted MSC, which was previously described in a model of vascular tissue engineering [30] .
It has been previously shown that ablated osteoclastogenesis significantly impaired bone formation by calcium phosphate implantations in ectopic sites [19] . However, the present study is the first to investigate hMSC-mediated osteoclast activity in bone formation. Increased bone formation was found when osteoclast and macrophage M0 and M1 presence was up-regulated at the implantation site by hMSC, and when osteoclastogenesis was abrogated a significant reduction in bone formation was significantly 6.0x10 -7 4.0x10 -7 2.0x10 -7 6.0x10 -7 4.0x10 -7 2.0x10 impaired. The precise underlying mechanisms are unclear, however several in vitro studies shed light on possible contributing factors such as the secretion of platelet-derived growth factor by osteoclasts which induces the migration of MSC [17] and the production of oncostatin M by monocyte/macrophages and osteoclasts which strongly induces the osteogenic differentiation of MSC in vitro [31, 32] . In the present study, in response to the implantation of BCP and hMSC, numerous macrophages M0 were observed around the particles and converted into pro-inflammatory M1. Co-implantation with human cells further enhanced this mechanism. Previous studies have shown that MSC can regulate the M1/M2 macrophage balance, favouring a shift towards the M2 anti-inflammatory phenotype [13, 15, 33] . This move towards the M2 phenotype has been implicated in the resolution of inflammation, tissue repair and remodelling in the heart [34] and kidney [35] . In contrast, the presence of macrophages M2 (study of 3 gene markers by PCR and 1 specific protein by immunohistochemistry), within implants with or without the addition of human cells was not observed in the current study. Therefore, macrophage M2 were shown not to be implicated in MSC mediated ectopic bone formation, rather macrophages M1 and osteoclasts were the prominent cells implicated in the ectopic osteogenesis mechanism. It would be interesting to study the macrophage role in bone formation, but independently of the osteoclast one. Alexander et al. have concluded that osteal macrophages promoted bone healing by using clodronate treatment and Macrophage Fas-Induced Apoptosis (MAFIA) transgenic mice model [16] . However, clodronate treatment and conditionally depletion of macrophages in MAFIA alter the osteoclast differentiation as well as the macrophage one. Furthermore, the MAFIA mouse model is in immune-competent mice and the bone formation mechanism should be differently addressed in an immune-deficient model, as suggested by recent study [36] .
In this study, the number of vascular cells within the implants was quantified and while the implants were observed to be highly vascularised, no difference between groups was observed. This suggests that there is no direct implication of vascularised tissue in this mechanism of ectopic bone formation induced by BCP granules and hMSC. 
Conclusion
Human MSC significantly enhanced ectopic bone formation in nude mice. They did not participate directly in osteogenesis, rather they increased the innate immune response and enabled to speed up the mobilization of monocytes to the implantation site where they differentiate into macrophages M1 and osteoclasts. Ablation of osteoclastogenesis by anti-RANKL treatment considerably impaired hMSC-mediated bone formation, highlighting the pivotal role of osteoclasts in the ectopic bone formation. In nude mice models, an up-regulation of osteoclasts and macrophages M1 at the implantation site was correlated with increased bone formation due to hMSC associated to BCP particles.
